BACKGROUND AND AIM: We present our experience in the use of the sutureless valve in @entity1 undergoing aortic valve replacement for pure @entity337 . METHODS: Out of 167 @entity1 who underwent sutureless aortic valve implantation with a Medtronic 3f Enable prosthesis in our unit between March 2011 and February 2014, 12 (7.1%) received a sutureless valve for pure @entity337 . RESULTS: Mean age, logistic EuroSCORE, and left ventricular ejection fraction were 72        5 years, 6.3        2.9%, and 52.5        15.3%, respectively. The sutureless valve could be successfully implanted in all cases; nine @entity1 had a full sternotomy (associated coronary artery bypass graft in four cases and associated mitral surgery in five), one @entity1 had a ministernotomy, and two had a thoracoscopic approach. Average cross-clamping and cardiopulmonary bypass times were 90        30 and 127        51 minutes, respectively. At the outpatient echocardiography, average mean gradient was 10.54        4.99   mmHg and a grade I-II paravalvular leakage (PVL) was detected in the first @entity1 of the cohort (ministernotomy approach). At a mean follow-up of 11.1        5.5 months, average mean gradient was 9.75        2.87   mmHg, no new PVL was detected, and the known PVL was stable. No pacemaker implantation was required. CONCLUSIONS: Implantation of the 3f Enable sutureless valve is technically possible with pure @entity337 in selected @entity1 . Multicenter investigations are necessary to assess the mid-term benefits of such a device in this subset of @entity1 .

Sutureless 3F Enable Valve Replacement for Pure XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity337 :: ('MESH:D001022', 'Disease') :: ['aortic regurgitation']
@entity337 :: (MESH:D001022,Disease) :: ['Aortic Regurgitation']
